Octave Bioscience announced a strategic collaboration with Quest Diagnostics to make the Octave Multiple Sclerosis Disease Activity (MSDA) Test accessible through Quest’s nationwide specimen-collection network.
Providers that order the test from Octave will be able to refer patients with a test requisition to one of Quest’s 7,000 patient service centers and in-office phlebotomists across the United States. It also gives Quest first rights to consider to provide specimen collection services for future novel tests Octave is developing for multiple sclerosis and Parkinson’s disease.
The Octave MSDA Test is the first and only clinically and analytically validated multi-analyte blood test that reports an MS disease activity score. It provides clinicians with reliable, objective data to support and inform proactive treatment decisions including whether or not to initiate, discontinue or switch a drug therapy. In a study published in Clinical Immunology, the MSDA Test outperformed a single biomarker (NfL) test, offering early detection and deeper insights into MS disease activity.
The Octave MSDA Test uses a simple blood test to measure 18 validated protein biomarkers, giving clinicians and patients a clear, data-driven view of disease activity to guide proactive treatment decisions. The test is reimbursed by multiple payers and supported by a patient affordability program. The MSDA Test is performed in Octave’s CLIA-certified, CAP-accredited, and New York State CLEP-approved laboratory in Menlo Park, California.
Read the full announcement on Businesswire
